Americans struggling with rising prescription drug costs may eventually benefit from a new federal rule designed to expose fees that have traditionally been difficult for employers to track. The U.S. Department of Labor has finalized regulations requiring pharmacy benefit managers (PBMs) to disclose more information about the money they receive while managing prescription coverage for large employer health plans.
The Department of Labor announced the final rule on October 29, 2026, saying the changes could help employers negotiate better prescription drug prices for workers and their families.
According to the agency, the rule could reduce prescription drug costs for health plans and participants by as much as $22 billion over 10 years, although that figure is a projection rather than guaranteed savings.
For Americans who regularly fill expensive prescriptions, the bigger question is whether greater transparency will eventually translate into lower costs at the pharmacy counter.
What Are Pharmacy Benefit Managers?
Pharmacy benefit managers operate behind the scenes in the prescription drug industry, helping employers and insurance plans manage medication coverage.
These companies negotiate with drug manufacturers, establish pharmacy networks, develop lists of covered medications, and process prescription drug claims.
According to the Department of Labor’s explanation of the new rule, PBMs can receive compensation from several sources, including employers, pharmaceutical manufacturers, and pharmacies.
Those complicated financial arrangements can make it difficult for employers to determine how much their prescription benefit services actually cost.
The new requirements are intended to give employers a clearer picture of those payments and help them evaluate whether their PBM contracts are financially reasonable.
What the New Rule Requires PBMs to Disclose
Under the finalized regulations, PBMs and affiliated brokers and consultants serving covered employer health plans must provide detailed information about their compensation.
The required disclosures include several types of payments that may not have been fully visible to employers previously:
- Drug manufacturer rebates: Payments and financial incentives received from pharmaceutical companies.
- Spread compensation: Money retained when a health plan pays more for a prescription than the PBM reimburses the pharmacy.
- Pharmacy clawbacks: Certain payments recouped from pharmacies in connection with prescriptions.
- Other compensation arrangements: Additional direct and indirect payments, including relevant price protection arrangements.
The rule also requires initial disclosures before covered contracts are entered into, renewed, or extended, followed by periodic reporting.
Employers will have the opportunity to audit disclosed compensation information at least annually, providing another mechanism for evaluating their PBM relationships.
Why This Matters for Your Prescription Drug Costs
Prescription drug expenses can take a substantial bite out of household budgets, especially for families managing chronic medical conditions.
Imagine an employee whose family fills several prescriptions every month through an employer-sponsored insurance plan.
If the employer discovers that its PBM receives substantial compensation through arrangements that were previously difficult to evaluate, it may be able to negotiate different contract terms.
Better contracts could potentially reduce employer healthcare spending, improve prescription benefits, or limit future increases in employee costs.
However, the rule does not directly require pharmacies to lower prices or employers to pass savings along to workers, so any financial benefit to individual consumers will depend on how health plans respond.
The Rule Could Affect Coverage for 90 Million Americans
The Department of Labor estimates that employer-sponsored self-insured group health plans using PBMs cover approximately 90 million Americans.
Self-insured plans are arrangements in which employers generally pay employees’ covered healthcare claims themselves rather than purchasing traditional fully insured coverage from an insurance company.
The new PBM disclosure requirements primarily target large self-insured plans, generally those with at least 100 participants or those sponsored by employers with at least 100 employees.
That means the rule could affect a substantial portion of the American workforce and their covered family members.
However, it is not a universal prescription drug pricing rule, and people enrolled in Medicare, Medicaid, or smaller fully insured employer plans should not assume their coverage will change because of these particular requirements.
When Will the New Requirements Take Effect?
The final regulation was published in the Federal Register on November 2, 2026.
It becomes effective January 4, 2027, but the disclosure requirements apply to plan years beginning on or after July 1, 2027.
This gives affected employers, PBMs, brokers, and consultants time to prepare for the new reporting obligations.
Workers should not expect an immediate reduction in their prescription copayments when the rule takes effect.
Any potential savings will likely depend on future contract negotiations, employer benefit decisions, and how the new transparency requirements influence PBM business practices.
What Workers Can Do to Reduce Prescription Costs Now
While the new rule may eventually improve prescription drug pricing, consumers don’t have to wait until 2027 to examine their existing costs.
Start by reviewing your employer’s prescription drug benefits, including medication tiers, deductibles, preferred pharmacies, and mail-order options.
If you take an expensive medication, ask your pharmacist or health plan whether a lower-cost generic or therapeutic alternative is available, and consult your prescriber before making changes.
You can also compare prices among participating pharmacies because the same medication may carry different out-of-pocket costs depending on your plan’s network arrangements.
For questions about employer-sponsored health coverage, the Employee Benefits Security Administration provides assistance at 1-866-444-3272.
Greater Transparency Could Be a First Step Toward Lower Drug Bills
The Labor Department’s new pharmacy benefit manager rule represents an effort to address financial arrangements that have long complicated the prescription drug marketplace.
By requiring PBMs to disclose more information about their compensation, federal regulators hope to give employers stronger tools for evaluating contracts and negotiating healthcare expenses.
Whether those changes ultimately reduce what Americans pay at the pharmacy counter remains to be seen.
For households already struggling with medication costs, the most important development will be whether increased transparency produces measurable savings in future health plans.
Have your prescription drug costs increased under your employer’s health insurance plan? Do you think greater transparency into pharmacy benefit manager fees will help bring prices down? Share your thoughts in the comments.
What to Read Next
A $0 Difference in Premium Can Still Mean Hundreds More in Healthcare Costs
Florida Health System Agrees to $541.5 Million Settlement Over Medicare Advantage Diagnosis Codes
What Trump’s New Healthcare Plan Proposes for Drug Prices, Insurance, and HSAs
Amanda Blankenship is the Chief Editor for District Media. With a BA in journalism from Wingate University, she frequently writes for a handful of websites and loves to share her own personal finance story with others. When she isn’t typing away at her desk, she enjoys spending time with her daughter, son, husband, and dog. During her free time, you’re likely to find her with her nose in a book, hiking, or playing RPG video games.